Rigel Pharmaceuticals (RIGL) Assets (2010 - 2026)

Rigel Pharmaceuticals' Assets history runs 17 years deep, the most recent figure standing at $504.6 million for Q1 2026.

• On a quarterly basis, Assets rose 186.75% year-over-year to $504.6 million in Q1 2026; TTM through Mar 2026 was $504.6 million, a 186.75% increase from a year earlier, with the FY2025 full-year figure at $513.6 million, up 213.21% from the prior year.
• Assets declined to $504.6 million in Q1 2026 per RIGL's latest filing, from $513.6 million in the prior quarter.
• Across five years, Assets topped out at $513.6 million in Q4 2025 and bottomed at $115.3 million in Q3 2023.
• The 5-year median for Assets is $134.3 million (2022), against an average of $188.4 million.
• Across the five-year window, Assets sank 38.02% in 2022 and surged 213.21% in 2025, its largest moves.
• Year by year, Assets stood at $134.3 million in 2022, then decreased by 12.7% to $117.2 million in 2023, then soared by 39.88% to $164.0 million in 2024, then jumped by 213.21% to $513.6 million in 2025, then decreased by 1.75% to $504.6 million in 2026.
• Per Business Quant, the three latest RIGL Assets figures stand at $504.6 million (Q1 2026), $513.6 million (Q4 2025), and $242.5 million (Q3 2025).